Orchid Chemicals & Pharmaceuticals Ltd. (Orchid), the Chennai-based pharma major today announced that it has been granted the Certificate of Suitability (CoS) by the European Directorate for the Quality of Medicines (EDQM) for its API product Cefadroxil Monohydrate. This is the 7th CoS that has been granted to Orchid.

“Europe is a key market in our overall regulated market strategy. We are focusing on a basket of products including premium high-value products as well as established ones. We now have 7 Certificates of Suitability (CoS) granted and we are confident of enlarging our business base in Europe during the coming quarters”, said K Raghavendra Rao, managing director, Orchid Chemicals & Pharmaceuticals Ltd.